Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
China Medical System Holdings Ltd (CMS), a subsidiary of Treasure Sea Ltd, is a pharmaceutical company that markets, promotes and sells pharmaceutical drugs. The company offers products such as diazepam nasal spray, sucroferric oxyhydroxide chewable tablets, recombinant human brain natriuretic peptide for injection, felodipine sustained release tablets, flupentixol and melitracen tablets, ganfule tablets, tildrakizumab injection, mucopolysaccharide polysulfate cream, polidocanol injection, azelaic acid acne removal series, and heling soothing product series, among others. Its pipeline products including SDN – 037 for eye pain and inflammation; PDP – 716 treats glaucoma and ocular hypertension; CF101 targets psoriasis; CF102 which treats hepatocellular carcinoma, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis; and others. CMS is headquartered in Hong Kong.
Headquarters
Hong Kong
Address
Unit 2106, 21/F, Island Place Tower, 510 King's Road, North Point, Hong Kong City
Website
web.cms.net.cn
Telephone
86 852 23697678
No of Employees
6,415
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
867 (HKG)
Revenue (2024)
$1.1B
9.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-8.1%
(2024 vs 2023)
Market Cap*
$3.9B
Net Profit Margin (2024)
XYZ
-16.4%
(2024 vs 2023)
* As of and is in US$
China Medical System Holdings Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Combizym |
| Tildrakizumab Solution for Injection | Ilumetri |
| Desidustat Tablets | Hirudoid |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In July, the company partnered with Insilico Medicine to target a mass-market central nervous system indication using a novel mechanism of action identified by PandaOmics. |
| 2026 | Contracts/Agreements | In April, the company entered into an agreement with Pharmacosmos A/S for Iron Isomaltoside Injection and Iron Dextran Injection. |
| 2026 | Regulatory Approval | In March, the company secured approval from the National Medical Products Administration of the People’s Republic of China for a new drug for renal anaemia, Desidustat Tablets. |
Competitor Comparison
| Key Parameters | China Medical System Holdings Ltd | China National Accord Medicines Corporation Ltd | Beijing Beilu Pharmaceutical Co Ltd | Hubei Guangji Pharmaceutical Co Ltd |
|---|---|---|---|---|
| Headquarters | Hong Kong | China | China | China |
| City | Hong Kong City | Shenzhen | Beijing | Huanggang |
| State/Province | - | Guangdong | Beijing | Hubei |
| No. of Employees | 6,415 | 28,336 | 1,188 | 1,164 |
| Entity Type | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Lam Kong | Chief Executive; President; Chairman | Executive Board | 2006 | 61 |
| Chen Yanling | Chief Financial Officer; Director; Vice President | Executive Board | 2006 | 55 |
| Huang Anjun | General Manager - Dermatology and Medical Aesthetic Business Division | Senior Management | - | 49 |
| Jiang Fei | Chief Investment Officer - Greater China | Senior Management | 2022 | 49 |
| James Stearns | Chief Investment Officer - Europe and America | Senior Management | 2021 | 46 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer